Investors optimistic about continued biotech and medtech IPO resurgence in 2025
When Australian biotech Telix Pharmaceuticals pulled a last-minute plug on its US public listing, it was yet another sign that…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a trainee reporter for Medical Device Network, covering developments in the healthcare sector. Coming from a scientific and medical background, Robert has reported across various topics with expertise in neuroscience, genetics, and epidemiology. Previously, he worked on a freelance basis with New Scientist.
-
-
FDA confirms end of Eli Lilly’s tirzepatide shortage after re-evaluation
The US Food and Drug Administration (FDA) has stood by an earlier decision confirming that the tirzepatide shortage is over.…
-
MSD makes obesity play in up to $2bn deal for Hansoh’s GLP-1RA asset
Merck & Co (MSD) has entered an exclusive global licence agreement with China-based Hansoh Pharma for a preclinical oral small…
-
FDA targets more online vendors selling unapproved GLP-1RA products
The US Food and Drug Administration (FDA) has issued warning letters to four companies selling unapproved glucagon-like peptide-1 receptor agonist…
-
EMA recommends expanding approval of Ofev to children and adolescents
Boehringer Ingelheim has won a positive European Medicines Agency (EMA) recommendation for blockbuster Ofev’s (nintedanib) use in children and adolescents…
-
Roche wins Vabysmo prefilled syringe EU approval to intensify Eylea challenge
The European Medicines Agency (EMA) has approved Roche’s Vabysmo (faricimab) in single-dose prefilled syringe form for three retinal conditions that…
-
UK indefinitely bans puberty blockers for teenagers due to “unacceptable risk”
Puberty blockers for people aged under 18 years with gender dysphoria will be indefinitely banned by the UK Government following…
-
Better prevention and treatment options needed for genital herpes, WHO says
A World Health Organization (WHO) director has called for “better prevention and treatment options” after the agency released new estimates…
-
Santhera’s DMD therapy Agamree approved for NHS use after new price deal
England’s National Institute for Health and Care Excellence (NICE) has recommended Santhera Pharmaceuticals’ treatment for Duchenne muscular dystrophy (DMD) Agamree…
-
Reprieve for Chinese biotechs as BIOSECURE Act left out of key bill
The future of the BIOSECURE Act was made more uncertain over the weekend after senators left the legislation out of…